Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

Pfizer/Hospira). Pfizer/Hospira). As of the March 23, 2020 transition, however, all “biological product” applications previously approved under the FD&C Act were “deemed” approved under the PHS Act, and companies can now seek biosimilars and interchangeables of these biological products. January 3, 2019. adalimumab-adaz.

Settlement 52

Settlement Litigation Marketing Marketing 52

43(B)log

FEBRUARY 7, 2022

Hospira, Inc., Deception/capacity to deceive: H-2 argued that the market here, including pharmacies, pharmacists, wholesalers, or insurance companies, are “sophisticated and well-acquainted with labeling strictures,” making deception implausible. In Belcher Pharmaceuticals, LLC v. 4th 1374, 1380–81 (11th Cir.

False Advertising 56

False Advertising Marketing Marketing Advertising 56

The IPKat

SEPTEMBER 23, 2021

The US Courts of Appeal of the Federal Circuit (CAFC) found in Belcher Pharmaceuticals v Hospira, Inc that a formulation patent was unenforceable in view of inequitable conduct, in the form of contradictory submissions to the patent office and the regulatory agency (FDA) by the patentee. adrenaline formulation into the market.

Patent Prosecution 57

Patent Prosecution Patent Patent Application Art 57

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Nivestym ® (Pfizer/ Hospira). Retacrit ® (Pfizer/Hospira).

Litigation 52

Litigation Settlement Patent Marketing 52